Direct-to-Consumer (DTC) Genetic Testing Market - By Technology (Single Nucleotide Polymorphism (SNP) Chips, Targeted Analysis, and Whole Genome Sequencing (WGS)), By Test Type (Predictive Testing, Carrier Testing, Nutrigenomics Testing, and Ancestry & Relationship Testing), and By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Description

The global Direct-to-Consumer (DTC) Genetic Testing market garnered revenue worth nearly 954.15 (USD Million) in 2019 and is set to record the CAGR of about 14.9% over the period from 2020 to 2026. The report offers assessment and analysis of the Direct-to-Consumer (DTC) Genetic Testing market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

Direct-to-consumer (DTC) genetic testing is referred to as genetic test that is sold directly to end-user through web, TV, or other marketing sites in the form of test kit without taking the Test Types of physicians or other healthcare Technologys. Moreover, these tests make use of next-generation sequencing technologies for testing the susceptibility of the consumers towards various kinds of ailments & traits.

Additionally, the breakthroughs in the genome sequencing technology have enabled DTC genetic testing firms to genotype many of the SNPs across gene with lesser costs. The improvements in genome sequencing technologies has sketched new paths for DTC genetic testing activities, thereby leading to creation of new firms such as 23andMe & Navigenics. Reportedly, these firms test people for myriad variants across gene related to complex disorders & usual traits.

Furthermore, there are wide array of tests available on internet. Some of the players of the Direct-to-consumer (DTC) genetic testing industry advertise tests for athletic ability and bitter taste insights. While other industry players highlight on healthcare-related products including carrier testing, testing for common ailment susceptibility, and pharmacogenomics testing.

In addition to this, many of the firms such as 23andMe and easyDNA UK offer susceptibility tests with latter offering predisposition DTC genetic testing for nearly 25 ailments such as atrial fibrillation, type 1 & type 2 diabetes, cancer, and multiple sclerosis.

Market Growth Factors

Direct-To-Consumer genetic tests offer information about genetic inclination towards a spectrum of disorders such as heart ailments, mental illness, diabetes, and Alzheimer. In addition to this, DTC genetic testing also offer information pertaining to genetic aspects that can affect the body reaction of the consumer to particular diet, pharmaceutical drugs, alcohol, and caffeine. Apparently, the tests also impart information about the genes that are related to eye color, athletic performance, and forms of male baldness. All these aforementioned factors are anticipated to accelerate the growth of Direct-To-Consumer (DTC) genetic testing market over the years to come.

Moreover, DTC testing provides a plethora of benefits to the end-users and are easily available at affordable prices. Additionally, consumer can order the testing kit online and hence the borders do not act as a barrier for the consumer to avail the Test Type. With the business witnessing rapid decline in the costs over the last few years, the of Direct-To-Consumer (DTC) genetic testing industry is likely to gain traction over the years ahead. All these aspects are expected to steer the surge in the Direct-To-Consumer (DTC) genetic testing market size over the forecast timeframe.

North America To Lead Overall Market Revenue Share Over 2020-2026

The regional market growth during the period from 2020 to 2026 is credited to altering view of end-users pertaining to genetic testing activities. Apart from this, rise in the per capita income in the countries like the U.S. and Canada has prompted the customers to expend more on direct-to-consumer genetic testing and the most prominent genetic tests being ancestral & nutrigenomics tests. This has resulted in rise in the interest and popularity of DTC genetic testing in the region, thereby leading to humungous growth of the market in the sub-continent.

Key participants profiled in the study include are Full Genomes, Pathway Genomics, MyHeritage, 23andMe, Ancestry, Genesis HealthCare,  Family Tree DNA, Color, Helix, EasyDNA, Identigene, Karmagenes, MapMyGenome, and Living DNA.

The global direct-to-consumer (DTC) genetic testing market is segmented as follows:

By Test Type

• Carrier Testing
• Predictive Testing
• Ancestry & Relationship Testing
• Nutrigenomics Testing

By Technology

• Targeted Analysis
• Single Nucleotide Polymorphism (SNP) Chips
• Whole Genome Sequencing (WGS)

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Direct-To-Consumer (DTC) Genetic Testing Market, 2016–2026(USD Million)
  • 2.2. Direct-To-Consumer (DTC) Genetic Testing Market: Snapshot
• Chapter 3. Global Direct-To-Consumer (DTC) Genetic Testing Market– Industry Analysis
  • 3.1. Direct-To-Consumer (DTC) Genetic Testing Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Affordability & easy availability of DTC genetic testing kits through internet
    • 3.2.2. Ability of the tests to provide information about genetic proclivity towards an array of disorders such as heart ailments, mental illness, diabetes, and Alzheimer to consumers.
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By Technology
    • 3.4.2. Market attractiveness analysis By Test Type
• Chapter 4. Global Direct-To-Consumer (DTC) Genetic Testing Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Direct-To-Consumer (DTC) Genetic Testing Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Direct-To-Consumer (DTC) Genetic Testing Market–Technology Analysis
  • 5.1. Global Direct-To-Consumer (DTC) Genetic Testing Market overview: By Technology
    • 5.1.1. Global Direct-To-Consumer (DTC) Genetic Testing Market share, By Technology,2019 and 2026
  • 5.2. Single Nucleotide Pulymorphism (SNP) Chips
    • 5.2.1. Global Direct-To-Consumer (DTC) Genetic Testing Market by Single Nucleotide Pulymorphism (SNP) Chips, 2016–2026(USD Million)
  • 5.3. Targeted Analysis
    • 5.3.1. Global Direct-To-Consumer (DTC) Genetic Testing Market by Targeted Analysis, 2016–2026(USD Million)
  • 5.4. Whule Genome Sequencing (WGS)
    • 5.4.1. Global Direct-To-Consumer (DTC) Genetic Testing Market by Whule Genome Sequencing (WGS), 2016–2026(USD Million)
• Chapter 6. Global Direct-To-Consumer (DTC) Genetic Testing Market– Test Type Analysis
  • 6.1. Global Direct-To-Consumer (DTC) Genetic Testing Market overview: By Test Type
    • 6.1.1. Global Direct-To-Consumer (DTC) Genetic Testing Market share, By Test Type , 2019 and 2026
  • 6.2. Predictive Testing
    • 6.2.1. Global Direct-To-Consumer (DTC) Genetic Testing Market By Predictive Testing, 2016–2026(USD Million)
  • 6.3. Carrier Testing
    • 6.3.1. Global Direct-To-Consumer (DTC) Genetic Testing Market By Carrier Testing, 2016–2026(USD Million)
  • 6.4. Nutrigenomics Testing
    • 6.4.1. Global Direct-To-Consumer (DTC) Genetic Testing Market By Nutrigenomics Testing, 2016–2026(USD Million)
  • 6.5. Ancestry & Relationship Testing
    • 6.5.1. Global Direct-To-Consumer (DTC) Genetic Testing Market By Ancestry & Relationship Testing, 2016–2026(USD Million)
• Chapter 7. Company Profiles
  • 7.1. 23andMe
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Ancestry
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Family Tree DNA
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Culor
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. Helix
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Development
  • 7.6. EasyDNA
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Development
  • 7.7. Full Genomes
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Development
  • 7.8. Identigene
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Development
  • 7.9. Karmagenes
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development
  • 7.10. Genesis HealthCare
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Product Portfolio
    • 7.10.4. Business Strategy
    • 7.10.5. Recent Development
  • 7.11. MapMyGenome
    • 7.11.1. Overview
    • 7.11.2. Financials
    • 7.11.3. Product Portfolio
    • 7.11.4. Business Strategy
    • 7.11.5. Recent Development
  • 7.12. MyHeritage
    • 7.12.1. Overview
    • 7.12.2. Financials
    • 7.12.3. Product Portfolio
    • 7.12.4. Business Strategy
    • 7.12.5. Recent Development
  • 7.13. Pathway Genomics
    • 7.13.1. Overview
    • 7.13.2. Financials
    • 7.13.3. Product Portfolio
    • 7.13.4. Business Strategy
    • 7.13.5. Recent Development
  • 7.14. Living DNA
    • 7.14.1. Overview
    • 7.14.2. Financials
    • 7.14.3. Product Portfolio
    • 7.14.4. Business Strategy
    • 7.14.5. Recent Development

Methodology